These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6851472)

  • 1. Short course chemotherapy for tuberculosis: treatment of choice?
    Buechner HA
    Compr Ther; 1983 May; 9(5):59-63. PubMed ID: 6851472
    [No Abstract]   [Full Text] [Related]  

  • 2. Short course chemotherapy for tuberculosis.
    McDonagh DJ
    J Ky Med Assoc; 1981 Mar; 79(3):153. PubMed ID: 7276708
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple small bowel perforations in a patient on treatment of tuberculosis.
    Scriven JM; Berry D
    J R Coll Surg Edinb; 1996 Oct; 41(5):353. PubMed ID: 8908966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Light and electron microscopy studies of the liver in tuberculosis patients receiving rifampin and isoniazid].
    Pilheu JA; de Salvo MC; Koch O; Barcat JA
    Medicina (B Aires); 1981; 41(4):439-45. PubMed ID: 7339434
    [No Abstract]   [Full Text] [Related]  

  • 5. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide.
    Geiter LJ; O'Brien RJ; Combs DL; Snider DE
    Tubercle; 1987 Jun; 68(2 Suppl):41-6. PubMed ID: 3318048
    [No Abstract]   [Full Text] [Related]  

  • 6. Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazed for primary treatment: the influence of various factors on the frequency of side-effects.
    Eule H; Werner E; Winsel K; Iwainsky H
    Tubercle; 1974 Mar; 55(1):81-9. PubMed ID: 4470836
    [No Abstract]   [Full Text] [Related]  

  • 7. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazid for primary treatment: the influence of various factors on the frequency of side-effects.
    Eule H; Werner E; Winsel K; Iwainsky H
    Tubercle; 1974 Mar; 55(1):81-9. PubMed ID: 4620295
    [No Abstract]   [Full Text] [Related]  

  • 9. Drugs for tuberculosis.
    Med Lett Drugs Ther; 1995 Aug; 37(954):67-70. PubMed ID: 7616907
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antitubercular chemotherapy].
    Jouveshomme S; Dautzenberg B
    Rev Mal Respir; 1997 Dec; 14 Suppl 5():S88-104. PubMed ID: 9496594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of the chemotherapy of tuberculosis. Part II.
    Lauver GL
    Ariz Med; 1978 Mar; 35(3):163-5. PubMed ID: 637730
    [No Abstract]   [Full Text] [Related]  

  • 12. [Studies on short-course chemotherapy of tuberculosis. II. Liver function during 6-month chemotherapy of tuberculosis with hydrazide, rifampicin and pyrazinamide].
    Nikodemowicz E; Kamińska M; Caban M; Struzik T
    Pneumonol Pol; 1984 Oct; 52(10):503-12. PubMed ID: 6533580
    [No Abstract]   [Full Text] [Related]  

  • 13. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):10-5. PubMed ID: 9562106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Five year follow-up study on the short-course chemotherapy for pulmonary tuberculosis in Niigata Prefecture].
    Hashimoto T; Shimao T; Aoki M; Misawa H; Takasawa N; Shiozawa S
    Kekkaku; 1984 Jun; 59(6):369-76. PubMed ID: 6492547
    [No Abstract]   [Full Text] [Related]  

  • 15. Short course chemotherapy of pulmonary tuberculosis and its possible impact on epidemiology of disease.
    Mehrotra ML; Gautam KD; Chaube CK
    Indian J Chest Dis Allied Sci; 1982; 24(2-3):195-202. PubMed ID: 7166353
    [No Abstract]   [Full Text] [Related]  

  • 16. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of pulmonary, pleural and vertebral tuberculosis].
    Favez G
    Schweiz Med Wochenschr; 1973 Jul; 103(30):1057-60. PubMed ID: 4719057
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hepatic tolerance in man of rifampicin-isoniazid association].
    Toulet J; Plomteux G; Viteau JM; Abiven M; Bonfante N
    J Med Liban; 1971; 24(6):651-8. PubMed ID: 5146848
    [No Abstract]   [Full Text] [Related]  

  • 19. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
    Ena J; Valls V
    Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up.
    Punnotok J; Pumprueg U; Chakorn T
    J Med Assoc Thai; 1995 Jun; 78(6):298-304. PubMed ID: 7561554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.